DRUG
Bright Minds·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
RSI Overbought
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DRUG
Bright Minds Biosciences Inc.
A biotech company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain
Biological Technology
05/31/2019
11/08/2021
NASDAQ Stock Exchange
0
09-30
Common stock
19 Vestry Street, New York, NY 10013
--
Bright Minds Biosciences Inc., was incorporated on May 31, 2019 under the British Columbia Business Companies Act. The company is a biotechnology company that develops treatments to improve the lives of patients with serious diseases. The company is creating new chemical entities as targeted therapeutic agents for the treatment of diseases with underlying pathologies driven by serotonin (5-HT) receptor (5-HT2A, 5-HT2C or 5-HT2A/C) mechanisms.
Company Financials
EPS
DRUG has released its 2024 Q1 earnings. EPS was reported at -0.44, versus the expected 0, missing expectations. The chart below visualizes how DRUG has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
